# Prostate cancer PSA level survival research

> Live situation record from CLSTR: https://clstr.news/situations/prostate-cancer-psa-level-survival-research
> Updated: 2026-08-26T07:24:24.000Z. Sources: 3. Developments: 2.

Research published in the journal CANCER indicates that achieving a prostate-specific antigen (PSA) level below 0.2 ng/mL within nine months of starting treatment is a significant predictor of survival for patients with metastatic hormone-sensitive (or castration-sensitive) prostate cancer.

Analyzing data from thousands of patients in the United States, the study suggests that this absolute threshold may be a more accurate prognostic indicator than the standard clinical metric of a 90% reduction in PSA levels. While a high percentage of patients achieved a 90% reduction, those who failed to reach the specific 0.2 ng/mL threshold faced higher mortality risks. The findings suggest that PSA levels could serve as a predictive biomarker to help guide personalized and potentially more aggressive treatment strategies.

## Timeline

### 2026-08-26: PSA levels below 0.2 ng/mL predict prostate cancer survival

A study of 4,890 US patients indicates that reaching a PSA level below 0.2 ng/mL within nine months of treatment is a strong predictor of long-term survival in metastatic castration-sensitive prostate cancer.

3 sources. https://clstr.news/cluster/psa-levels-below-02-ngml-predict-prostate-cancer-survival

### 2026-08-10: PSA level below 0.2 ng/mL linked to improved prostate cancer survival

A study of nearly 4,900 patients shows that reaching a PSA level below 0.2 ng/mL within nine months is linked to significantly improved survival in metastatic prostate cancer cases.

2 sources. https://clstr.news/cluster/psa-level-below-02-ngml-linked-to-improved-prostate-cancer-survival

---
Cite as: Prostate cancer PSA level survival research. CLSTR, https://clstr.news/situations/prostate-cancer-psa-level-survival-research